Climb Bio Inc (CLYM) USD0.0001
Sell:$1.15Buy:$1.26
$0.06
(4.96%)
- This stock can be held in a
Stocks and Shares ISA$0.06
(4.96%)$0.06
(4.96%)Company Information
About this company
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Key people
Key facts
- EPICCLYM
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS28658R1068
- Market cap$80.97m
- Employees17
- Shares in issue67.48m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.